Navigation Links
A Drug With Efficacy Superior to That of Remicade at Inducing Closure and Healing of Fistulas Would Earn a 30 Percent Patient Share in the Crohn's Disease Drug Market
Date:6/11/2008

Ustekinumab Will Earn a 5.4 Percent Patient Share by 2012, According to a

New Report from Decision Resources

WALTHAM, Mass., June 11 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a therapy that induces closure and healing of fistulas in a greater percentage of patients than Centocor/Schering-Plough/Mitsubishi Tanabe's Remicade (infliximab) does, would earn a 30 percent patient share in the treatment of Crohn's disease, according to surveyed gastroenterologists.

The new report entitled Crohn's Disease: Physicians Seek Drugs That Treat Fistulizing Disease More Effectively than Infliximab finds that surveyed gastroenterologists indicated that they would prescribe Centocor/Janssen-Cilag's ustekinumab to 30 percent of their patients with Crohn's disease. As a result, ustekinumab is forecasted to earn a 5.4 percent patient share of the U.S. Crohn's disease market in 2012.

The report also finds that UCB's Cimzia will earn Decision Resources' proprietary clinical gold standard ("clinical gold standard") status for the treatment of Crohn's disease by 2011 as interviewed gastroenterologists indicate that Cimzia's efficacy and delivery profiles are superior to those of the current clinical gold standard, Abbott/Eisai's Humira. Although surveyed gastroenterologists indicated that Cimzia has advantages in efficacy and delivery, the therapy may be associated with more minor side effects when compared to Humira.

"Interviewed gastroenterologists report that Cimzia's pegylated formulation may prolong the drug's effect, resulting in a slightly more effective maintenance therapy with a superior maintenance dosing schedule in comparison to Humira," said Kathryn Benton, analyst at Decision Resources. "As a result, we forecast Cimzia to replace Humira as the clinical gold standard because of its incremental advantage in delivery and maintenance of clinical remission."

About the Report

Crohn's Disease: Physicians Seek Drugs That Treat Fistulizing Disease More Effectively than Infliximab is a DecisionBase 2008 report from Decision Resources. DecisionBase 2008 combines market forecasts with clinical and commercial end points to assess market share projections in 35 indications. These outputs are driven by quantitative and qualitative primary research. DecisionBase 2008 provides detailed market share, patient share, and price-per-day projections for emerging drugs in development. The market share projections are based on prescriber surveys that compare physicians' expectations of a potential target product profile with an emerging product profile of the leading drugs in development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources, Inc. (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

For more information, contact:

Elizabeth Marshall

Decision Resources

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. USC researchers identify genetic markers that predict efficacy of novel cancer drug
2. Ohio State University Medical Center to Test Efficacy of Hyperbaric Oxygen Medicine on Stroke Victims
3. Pilot Study to Assess Safety and Efficacy of Medidur(TM) FA in AMD Patients Treated With Lucentis(R)
4. Shire investigational nonstimulant INTUNIV showed significant efficacy in reducing ADHD symptoms
5. Efficacy of FluMist(R) in Children Highlighted at Pediatric Academic Societies Meeting
6. Labopharm Appeals FDAs Decision on Once-Daily Tramadol to Next Supervisory Level After Additional Analysis Supports Efficacy
7. Gamma Secretase Modulators Show Promise in Alzheimers Disease Animal Model Efficacy Studies, According to Research Conducted by TorreyPines Therapeutics
8. Largest ever analysis of DES data demonstrates safety, efficacy in on-and-off-label use
9. GSK Data Suggests Efficacy of Advair(R) and Serevent(R) is Not Impacted by Genetic Profile
10. A Drug With Efficacy Superior to That of Memantine Would Earn up to a 50% Patient Share in the Moderate-to-Severe Alzheimers Disease Drug Market
11. What are simple ways to judge the efficacy of 5-fluorouracil in colonic neoplasm?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) of Somerset ... of specialty vendors and unique items from across the nation, this holiday-themed event will ... services offered by the VNA. The boutique will be open Saturday, November 4 ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, ... Development, has been awarded a contract by the Center for Medicare and Medicaid ... to accelerate the enterprise use of Agile methodologies in a consistent and high ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the ... today its plans to open a flagship location in Covington, LA at 401 N. ... To Go store next to Office Depot in the Holiday Square shopping center. Its ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... delivery system that we intend to develop to enable prevention of a major ... to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is ...
(Date:10/12/2017)... GRAND RAPIDS, Mich. (PRWEB) , ... October 12, ... ... OnSite Wellness, has been named one of Michigan’s 2017 Best and Brightest in ... Best and Brightest in Wellness® awards program on Friday, Oct. 20 from 7:30 ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... COUNTY, Calif. , Oct. 10, 2017  NDS received FDA ... Mobile  — a medical-grade battery-powered display stand specifically designed for endoscopy ... to transform technology into a clinical solution to support the improvement ... Innovative Design ... ZeroWire Mobile Wireless Solution ...
(Date:10/7/2017)... Oct. 6, 2017   Provista, a proven ... $100 billion in purchasing power, today announced a new ... The Newsroom is the online home for ... infographics, expert bios, news releases, slideshows and events. ... a wealth of resources at their fingertips, viewers can ...
(Date:10/4/2017)... Korea , Oct. 4, 2017  South Korean-based ... next-generation CPR training aide "cprCUBE" on Kickstarter. The device ... compression during cardiac arrests with better efficiency compared to ... also offers real-time feedback on efficacy of the compression ... crowdfunding campaign has a goal to raise $5,000. ...
Breaking Medicine Technology: